Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Sarina A Piha-PaulChristine L HannChristopher A FrenchSophie CousinIrene BrañaPhillippe A CassierVictor MorenoJohann S de BonoSara Duckworth HarwardGeraldine Ferron-BradyOlena BarbashAnastasia WyceYuehui WuThierry HornerMeg AnnanNigel J ParrRabinder K PrinjhaChristopher L CarpenterJohn HiltonDavid S HongNaomi B HaasMark C MarkowskiArindam DharPeter J O'DwyerGeoffrey I Shapiro

Published in: JNCI cancer spectrum (2019)

Once-daily molibresib was tolerated at doses demonstrating target engagement. Preliminary data indicate proof-of-concept in NC.

Keyphrases

electronic health record
open label
social media
signaling pathway
physical activity
big data
pi k akt
protein protein
amino acid
binding protein
double blind
small molecule